Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | CA7 | P43166 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21064874 | 0.91 | TSHR (1.00) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL19193 | 0.91 | — | — | |
| Ammonia Solution, Strong SCHEMBL5086843 | 0.88 | — | — | |
| SCHEMBL4431010 | 0.88 | TSHR (0.93) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Water SCHEMBL1289230 | 0.88 | — | — | |
| Methyl Alcohol SCHEMBL584909 | 0.88 | — | — | |
| SCHEMBL1278490 | 0.88 | — | — | |
| SCHEMBL3495565 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL2107550 | 0.88 | — | — | |
| SCHEMBL28357409 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023202651-A1 | POLYMORPHIC FORMS OF GLUTAMINE ANTAGONIST AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | WO | claimed |
| CN-110872269-B | Salt of cyclohexane derivative | 浙江京新药业股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-11897848-B2 | Crystalline forms of ozanimod and processes for preparation thereof | RECEPTOS LLC (US) | 2024-02-13 | — | — | US | disclosed |
| EP-3848360-B1 | MALEIC ACID SALT OF A CYCLOHEXANE DERIVATIVE | ZHEJIANG JINGXIN PHARMACEUTICAL CO LTD (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230339975-A1 | CRYSTALLINE FORM OF SHP2 INHIBITOR, AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023202651-A1 | POLYMORPHIC FORMS OF GLUTAMINE ANTAGONIST AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | WO | disclosed |
| EP-4169920-A1 | CRYSTALLINE FORM OF SHP2 INHIBITOR, AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| US-11584731-B2 | Salt of cyclohexane derivative | SHANGHAI JINGXIN BIOLOGY & PHARMACEUTICAL CO., LTD (CN) | 2023-02-21 | — | — | US | disclosed |
| CN-115698007-A | Crystal form of SHP2 inhibitor, composition, preparation method and application thereof | 上海奕拓医药科技有限责任公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021254449-A1 | CRYSTALLINE FORM OF SHP2 INHIBITOR, AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海奕拓医药科技有限责任公司 | 2021-12-23 | — | — | WO | disclosed |
| EP-2421849-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Theravance, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2367829-A1 | NOVEL FORMS OF AN INDAZOLO [5,4-A] PYRROLO [3,4-C] CARBAZOLE COMPOUND | Cephalon, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230508-A1 | Novel Forms of a Fused Pyrrolocarbazole Compound | CEPHALON, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20100273755-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-10-28 | — | — | US | disclosed |
| WO-2010123766-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010059795-A1 | NOVEL FORMS OF AN INDAZOLO [5,4-A] PYRROLO [3,4-C] CARBAZOLE COMPOUND | CEPHALON, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
| US-5700810-A | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| US-4695589-A | HYPOTENSIVE AGENTS | STERLING DRUG INC. (US) | 1987-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230508-A1 | Novel Forms of a Fused Pyrrolocarbazole Compound | NUP188, MCL1, AURKAIP1 | TSHR 3967/4885CHRM2 4863/4885CHRM4 4834/4885 |
| US-11897848-B2 | Crystalline forms of ozanimod and processes for preparation thereof | SOST, CD59, UACA | TSHR 2601/4885CHRM2 130/4885CHRM4 144/4885 |
| US-11584731-B2 | Salt of cyclohexane derivative | SLC34A2, SLC34A1, SLC14A1 | TSHR 1596/4885CHRM2 3986/4885CHRM4 4592/4885 |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | TSHR 62/4885CHRM2 347/4885CHRM4 509/4885 |
| US-20100273755-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2A | TSHR 133/4885CHRM2 10/4885CHRM4 27/4885 |
| US-20230339975-A1 | CRYSTALLINE FORM OF SHP2 INHIBITOR, AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | PTPN1, PTPN11, PTPN7 | TSHR 2903/4885CHRM2 4811/4885CHRM4 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.